Nightstar Therapeutics (NITE) Competitors

Nightstar Therapeutics (NASDAQ:NITE) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.

Which has more risk & volatility, NITE or KRYS?

Nightstar Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in NITE or KRYS?

32.8% of Nightstar Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer NITE or KRYS?

In the previous week, Krystal Biotech had 7 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 7 mentions for Krystal Biotech and 0 mentions for Nightstar Therapeutics. Krystal Biotech's average media sentiment score of 1.42 beat Nightstar Therapeutics' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Nightstar Therapeutics	Neutral
Krystal Biotech	Positive

Does the MarketBeat Community believe in NITE or KRYS?

Krystal Biotech received 74 more outperform votes than Nightstar Therapeutics when rated by MarketBeat users. However, 69.88% of users gave Nightstar Therapeutics an outperform vote while only 67.80% of users gave Krystal Biotech an outperform vote.

Company	Underperform	Outperform
Nightstar Therapeutics	Outperform Votes 225 69.88%	Underperform Votes 97 30.12%
Krystal Biotech	Outperform Votes 299 67.80%	Underperform Votes 142 32.20%

Which has preferable earnings and valuation, NITE or KRYS?

Krystal Biotech has higher revenue and earnings than Nightstar Therapeutics. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nightstar Therapeutics	N/A	N/A	-$36.86M	-$1.26	-23.76
Krystal Biotech	$333.45M	11.80	$10.93M	$4.16	32.74

Do analysts prefer NITE or KRYS?

Krystal Biotech has a consensus price target of $211.13, indicating a potential upside of 55.02%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Krystal Biotech is more favorable than Nightstar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nightstar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is NITE or KRYS more profitable?

Krystal Biotech has a net margin of 30.69% compared to Nightstar Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 11.41% beat Nightstar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nightstar Therapeutics	N/A	-30.89%	-27.65%
Krystal Biotech	30.69%	11.41%	10.40%

Summary

Krystal Biotech beats Nightstar Therapeutics on 16 of the 18 factors compared between the two stocks.